News

Patients and clinicians perceived a gap that largely didn't exist in views on diet's role in IBD.

FDA approves pegcetacoplan (Empaveli) for treating C3 glomerulopathy and primary IC-MPGN, offering hope for patients aged 12 and older.

Elkady joins the program to discuss her experience transitioning from patient care to clinical trials and industry.

A multidisciplinary care program achieved a 95% cure rate with Sofosbuvir/Velpatasvir therapy.

Deming explains drivers of new infections, systemic barriers impeding progress, and the changes she believes are needed to aid elimination efforts.

This interview with Cotter highlights his session on the use of AI tools in the dermatology field.

Sands describes the current landscape of Crohn’s disease therapies and reviews GALAXI 2 and 3 data supporting guselkumab’s role in evolving care paradigms.

Anti-TNF therapies show strong 3-year durability in pediatric IBD, with new clinical markers helping predict early nonresponse in Crohn’s disease and UC/IBD-unclassified cases.

A study investigating frequently used treatments, mean duration from first symptom to index date, and disease phenotypes found most cases are mild to moderate.

The approval was based on positive results from the phase 3 foresiGHt trial and expands upon the indication for pediatric growth hormone deficiency.

A new study highlights stress, concussion, and other early-life factors as key contributors to pediatric pain-predominant DGBIs.

Swanson speaks in this interview segment about her DERM 2025 session on speaking with parents and their children or teens as a clinician.

This interim data was drawn from the TRACE study, highlighting real-world use of tralokinumab in adults with atopic dermatitis of the head and neck.

In this interview, Swanson highlights her DERM 2025 session ‘Systemic Therapy for the Pediatric Acne Patient’ and its takeaways.

In this DERM2025 interview, Friedman highlighted some of the discussion points from his presentation on off-label strategies for therapeutic challenges.

In this interview segment with Chilukuri, he highlights takeaways from his DERM 2025 session titled ‘Advancements in Body Contouring.’

In this discussion with Chilukuri, the most notable highlights from his DERM 2025 session ‘Skincare Secrets and Quick Fixes’ were covered.

In this interview, Friedman highlights notable points from his DERM 2025 talk on managing patients with tinea.

Combination therapy results in an overall reduction in 1-year mortality and hospitalizations compared to patients receiving SGLT2 inhibitors alone.

In a new interview at the DERM2025 Conference, Boswell highlights a session on systemic drugs and another session on wart and molluscum imitators.

In a new interview at the DERM2025 Conference, Stein Gold highlighted several topical options for patients with psoriasis outside of topical steroids.

This interview with Friedman highlights the takeaways from his DERM 2025 session on managing chronic pruritus in dermatology.

A new study found older adults with insomnia experience significantly greater and longer-lasting depressive symptoms after inflammatory exposure.

In an ADvocate study subpopulation, new findings suggest lebrikizumab therapy leads to significant disease control and positive itch impacts.

A recent study has suggested the efficacy of a common type 2 diabetes treatment in improving cardiac structure and metabolic control.

New research finds patients with severe allergic asthma had greater emotional regulation than those with venom anaphylaxis, despite reporting poorer physical well-being.

Li and Shao discussed the T2D risk reduction seen over the course of the VA MOVE! lifestyle intervention program for veterans.

This summary highlights changes in severe alopecia areata following deuruxolitinib therapy during THRIVE-AA1 and THRIVE-AA2.